» Articles » PMID: 34080787

Vitamin D and Vitamin D-binding Protein and Risk of Bladder Cancer: A Nested Case-control Study in the Norwegian Janus Serum Bank Cohort

Overview
Journal Cancer Med
Specialty Oncology
Date 2021 Jun 3
PMID 34080787
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: High circulating levels of vitamin D (25(OH)D) are suggested to reduce the risk of urinary bladder cancer (BC), but the evidence is weak, and several studies lack sufficient adjustment for potential confounders (e.g., smoking, body mass index (BMI), and physical activity). Moreover, few studies have investigated the role of vitamin D-binding protein (DBP) in this context. We conducted a matched nested case-control study including 378 cases and 378 controls within the Norwegian population-based Janus cohort, using serum collected 5-41 years prior to diagnosis, to study 25(OH)D and BC risk, by taking circulating DBP into account.

Methods: Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), for 25(OH)D, DBP, and the molar ratio of 25(OH)D:DBP, an estimate of unbound (free) 25(OH)D levels. We adjusted for smoking (status and pack-years), BMI, physical activity, education and (mutually) for 25(OH)D and DBP. Restricted cubic splines were employed to examine nonlinear associations.

Results: High optimal levels of circulating 25(OH)D (≥100 nmol/L) (HR 0.35, 95% CI 0.19-0.64) were associated with decreased BC risk, when compared with insufficient concentrations (50-74 nmol/L). This association was less pronounced for optimal levels (75-99 nmol/L) (HR = 0.69, 95% CI 0.47-1.01). Moreover, estimated free 25(OH)D, was associated with decreased BC risk for molar ratio 17-21 (HR 0.66, 95% CI 0.44-0.97) and ≥22 (HR 0.50, 95% CI 0.29-0.82), compared to molar ratio 11-16. The HR function for BC risk was not linear, rather reversed u-shaped, with the highest HR at 62.5 nmol/L and 13.5 molar ratio, respectively.

Conclusion: High levels of total and estimated free 25(OH)D were associated with reduced risk of BC, compared with insufficient concentrations. DBP was not associated with BC risk. We did not observe any impact of DBP or any of the studied lifestyle factors on the association between 25(OH)D and BC.

Citing Articles

Can the use of antithrombotic drugs be a predictive factor in the early diagnosis of bladder cancer?: A single-center analysis.

Ekici M, Demir E, Aydin C, Caglayan M, Ozgur B, Baykam M Medicine (Baltimore). 2024; 103(20):e38228.

PMID: 38758868 PMC: 11098255. DOI: 10.1097/MD.0000000000038228.


Circulating vitamin D concentration and risk of 14 cancers: a bidirectional Mendelian randomization study.

Dai Y, Chen Y, Pu Y, Jiang R J Cancer Res Clin Oncol. 2023; 149(17):15457-15467.

PMID: 37642723 DOI: 10.1007/s00432-023-05322-9.


Prediagnostic Serum 25-Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort.

Hektoen H, Gislefoss R, Stenehjem J, Langseth H, Axcrona K, Mondul A Clin Epidemiol. 2021; 13:801-811.

PMID: 34548821 PMC: 8449552. DOI: 10.2147/CLEP.S319620.

References
1.
Hofmann J, Yu K, Horst R, Hayes R, Purdue M . Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2010; 19(4):927-31. PMC: 2857993. DOI: 10.1158/1055-9965.EPI-09-1121. View

2.
Kubiak J, Kamycheva E, Jorde R . Tracking of serum 25-hydroxyvitamin D during 21 years. Eur J Clin Nutr. 2020; 75(7):1069-1076. DOI: 10.1038/s41430-020-00814-0. View

3.
Konety B, Lavelle J, Pirtskalaishvili G, Dhir R, Meyers S, Nguyen T . Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol. 2000; 165(1):253-8. DOI: 10.1097/00005392-200101000-00074. View

4.
Hill A . THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION?. Proc R Soc Med. 1965; 58:295-300. PMC: 1898525. DOI: 10.1177/003591576505800503. View

5.
Hjerkind K, Gislefoss R, Tretli S, Nystad W, Bjorge T, Engeland A . Cohort Profile Update: The Janus Serum Bank Cohort in Norway. Int J Epidemiol. 2017; 46(4):1101-1102f. DOI: 10.1093/ije/dyw302. View